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Abstract
Background: Previously, we found that b-galactoside a2,6-sialyltransferase (ST6Gal I), an enzyme that adds sialic
acids to N-linked oligosaccharides of glycoproteins and is frequently overexpressed in cancer cells, is up-regulated
by ionizing radiation (IR) and cleaved to a form possessing catalytic activity comparable to that of the Golgi-
localized enzyme. Moreover, this soluble form is secreted into the culture media. Induction of ST6Gal I significantly
increased the migration of colon cancer cells via sialylation of integrin b1. Here, we further investigated the
mechanisms underlying ST6Gal I cleavage, solubilization and release from cells, and addressed its functions,
focusing primarily on cancer cell migration.
Methods: We performed immunoblotting and lectin affinity assay to analyze the expression of ST6 Gal I and level
of sialylated integrin b1. After ionizing radiation, migration of cells was measured by in vitro migration assay. a2, 6
sialylation level of cell surface was analyzed by flow cytometry. Cell culture media were concentrated and then
analyzed for soluble ST6Gal I levels using an a2, 6 sialyltransferase sandwich ELISA.
Result: We found that ST6Gal I was cleaved by BACE1 (b-site amyloid precursor protein-cleaving enzyme), which
was specifically overexpressed in response to IR. The soluble form of ST6Gal I, which also has sialyltransferase
enzymatic activity, was cleaved from the Golgi membrane and then released into the culture media. Both non-
cleaved and cleaved forms of ST6Gal I significantly increased colon cancer cell migration in a sialylation-dependent
manner. The pro-migratory effect of the non-cleaved form of ST6Gal I was dependent on integrin b1 sialylation,
whereas that of the cleaved form of ST6Gal I was not, suggesting that other intracellular sialylated molecules apart
from cell surface molecules such as integrin b1 might be involved in mediating the pro-migratory effects of the
soluble form of ST6Gal I. Moreover, production of soluble form ST6Gal I by BACE 1 inhibited integrin b1 sialylation
and migration by Golgi-anchored form of ST6Gal I.
Conclusions: Our results suggest that soluble ST6Gal I, possibly in cooperation with the Golgi-bound form, may
participate in cancer progression and metastasis prior to being secreted from cancer cells.
Keywords: BACE1, Migration, Radiation, ST6Gal I
* Correspondence: ygko@korea.ac.kr; yslee0425@ewha.ac.kr
† Contributed equally
2College of Life Sciences and Biotechnology, Korea University, 1, 5-ka,
Anamdong, Sungbuk-gu, Seoul 136-701, South Korea
3College of Pharmacy & Division of Life & Pharmaceutical Sciences, Ewha
Womans University, 11-1 Daehyun-Dong, Seodaemun-Gu, Seoul 120-750,
South Korea
Full list of author information is available at the end of the article
Lee et al. Radiation Oncology 2012, 7:47
http://www.ro-journal.com/content/7/1/47
© 2012 Lee et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Background
ST6Gal I (b galactoside a2,6 sialyltransferase, CMP-
NeuAc: Galb (1,4) GlcNAc: a2,6 sialyltransferase) is an
important glycosyltransferase that adds a sialic acid resi-
due to the terminal position on N-linked oligosacchar-
ides [1,2]. It is localized in the Golgi apparatus in a
membrane-anchored form and is cleaved into a secre-
tary protein by cathepsin-like proteases [3]. Recent stu-
dies and clinical reports have emphasized the
importance of ST6Gal I in cancer progression and
metastasis. ST6Gal I is up-regulated in colon adenocar-
cinoma and its expression is positively associated with
tumor cell migration and invasion [4-6]. Specifically,
patients with metastasizing tumors have high levels of
ST6Gal I in their serum, and serum levels of ST6Gal I
are correlated with the progression of colorectal carci-
nomas and cancer metastasis [7-13]. However, a possible
biological role of ST6Gal I in the plasma has not been
reported.
Metastasis represents an obligatory step in cancer
progression. A variety of molecules contribute to can-
cer progression and metastasis [14], and many of the
factors that function in tumor metastasis are glycopro-
teins [15-17]. It has been previously demonstrated that
integrin b1 is a major substrate of ST6Gal I [4,18]. In
colon epithelial cells, oncogenic Ras has been shown to
up-regulate ST6Gal I expression, leading to increased
a-2,6 sialylation of b1 integrin [19]. Hypersialylation of
integrin b1 augments colon cancer metastasis by alter-
ing cellular preference for a certain extracellular matrix
milieu as well as by stimulating cell migration. Integ-
rins also regulate cellular functions, including survival,
proliferation and cell spreading, through the function
of signaling molecules co-localized to the focal adhe-
sion complex [20,21]. We have previously demon-
strated that exposure to ionizing radiation (IR)
increases the expression of ST6Gal I as well as the
level of sialylated glycoprotein. Sialylation of integrin
b1 by exposure of cells to IR increases the adhesion
and migration of colon cancer cells through integrin
b1-mediated cellular signaling. Therefore, integrin b1
sialylation and the subsequent activation of p130CAS,
paxillin, and AKT signaling may be one of the
mechanisms involved in IR-mediated-radioresistance
and cancer metastasis [22-26].
b-site amyloid precursor protein-cleaving enzyme
(BACE) is a membrane-bound aspartic protease that
cleaves the amyloid precursor protein (APP) in the
pathogenesis of Alzheimer’s disease [27,28]. Importantly,
BACE has been identified as a protease responsible for
the cleavage and secretion of Golgi-resident ST6Gal I
[29]. The mechanisms underlying cleavage are compli-
cated, and have not been well characterized. Soluble
forms of glycosyltransferases exist in the plasma of
patients with certain diseases, and can sometimes be
used as biomarkers for these diseases [30-33].
In the present study, we examined IR-induced clea-
vage and solubilization of ST6Gal I, which is released
into the cell culture media of colon cancer cell lines,
and sought to identify the protease involved in cleaving
ST6Gal I after exposure to IR. We found that BACE1
could be the secretase responsible for IR-induced clea-
vage of ST6Gal I, and showed that BACE1 mediated
cleavage of ST6Gal I decreased ST6Gal I -mediated can-
cer cell migration. Additionally, the soluble form of
ST6Gal I possesses sialyltransferase enzymatic activity,
but unlike the Golgi-associated form, did not sialylate
integrin b1 to a significant degree, suggesting that solu-
ble ST6Gal I, possibly in cooperation with the Golgi-
bound form, may participate in cancer progression and
metastasis before being secreted from cancer cells, inde-
pendent of intergrin b1-sialylation.
Materials and methods
Cell culture
SW480 and SW48 human colorectal carcinoma cells
were grown in RPMI media supplemented with heat-
inactivated 10% fetal bovine serum and antibiotics.
CT26 mouse colorectal carcinoma cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with heat-inactivated 10% fetal bovine serum
and antibiotics.
Plasmids and transfection
For transient transfection experiments, expression con-
structs of C-terminally Flag-tagged wild-type (WT; p3 ×
Flag-ST6Gal I) ST6Gal I and N-terminally deleted (HA-
tagged) ST6Gal I (ST6Gal I ΔN) were created as
described previously [23]. An N-terminally Flag-tagged
double-mutant, ST6Gal I (L37A/K40A) was created by
site-directed mutagenesis [34]. Predesigned small inter-
fering RNA (siRNA) for ST6Gal I was purchased from
Dharmacon (Lafayette, CO, USA). BACE-1 was targeted
with the siRNA duplex 5’-AGA UCC UGU CCA UUG
AU CUC CAC CC-3’ and 5’-GGG UGG AGA UCA
AUG GAC AGG AUC U-3’ [35]. A BACE-1 expression
plasmid (pcDNA3.1/BACE-1) was generously provided
by Dr. Sul-Hee Chung (Inje University, Pusan, Korea)
[36]. Cells were transfected with plasmids using Lipofec-
tAMINE 2000 (Invitrogen, Carlsbad, CA, USA) as
described by the manufacturer.
Irradiation
Cells were exposed to g-irradiation using a 137Cs g-ray
source (Atomic Energy of Canada, Mississauga, ON,
Canada) at a dose rate of 3.81 Gy/min.
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Immunoblot, lectin affinity assay, and
immunoprecipitation
Protein levels were detected using the following commer-
cial antibodies: anti-integrin b1 (BD Biosciences, Franklin
Lakes, NJ, USA); anti-phospho-p130CAS, anti-phospho-
Src, anti-HA, and anti-Myc (Cell Signaling Technology,
Danvers, MA, USA); anti-Flag (Sigma); and anti-ST6Gal I
and anti-BACE-1 (IBL, Japan). For detection of sialylated
proteins, cell lysates were incubated with biotinylated SNA
(Sambucus Nigra lectin; Vector Laboratories, Burlingame,
CA, USA), and protein-lectin complexes were precipitated
with avidin-coated protein A-agarose (Sigma).
Flow cytometry
Cells were detached with trypsin/EDTA at the indicated
times and stained with fluorescein isothiocyanate
(FITC)-conjugated SNA (FITC-SNA) or Maackia amur-
ensis (FITC-MAA) lectin (Vector Laboratories, Burlin-
game, CA, USA) for detection of a2,6 and a2,3
sialylation, respectively. After staining, fluorescence
intensity was analyzed by fluorescence-activated cell
sorting (FACS).
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated with TRI reagents (Molecular
Research Center), and reverse transcription was done
using Omniscript transcriptase (Qiagen) under the fol-
lowing thermocycling conditions: 30 cycles of 95°C for 5
min (denaturing), 60°C for 30 s (annealing), and 72°C
for 30 seconds (extension). The primer sequences used
were as follows: human BACE1, 5’-GGT GGA GAT
CAA TGG ACA GG-3’ (sense) and 5’-CGT GGA TGA
CTG TGA GAT GG-3’ (antisense); mouse Bace1, 5’-
GCA GAC CCA CAT TCC GAA CA-3’ (sense) and 5’-
GCC ACT GTC CAC GAT GCT CTT-3’ (anti-sense);
and GAPDH, 5’-CAT GGA GAA GGC TGG GGC TCA
TTT-3’ (sense) and 5’-CGC CAG TAG AGG CAG
GGA TGA TGT-3’ (antisense).
In vitro migration assay
Cell migration assays were performed using a Boyden
chamber as previously described [24]. Cells were plated
on the upper side of a collagen treated, polycarbonate
membrane separating two chambers of 6.5-mm Trans-
well culture plates (Costar, Corning, NY, USA). After 24
hours, cells on the upper face of the membrane were
scraped using a cotton swab and cells that had migrated
to the lower face of the membrane were stained with
DiffQuick (Baxter Scientific, Deerfield, IL, USA) Wright-
Giemsa Solution.
Soluble ST6Gal I ELISA
Cell culture media were concentrated using Centricon
centrifugal filter devices (Millipore, Billerica, MA, USA)
and then analyzed for soluble ST6Gal I levels using an
a2,6 sialyltransferase sandwich enzyme-linked immuno-
sorbent assay (ELISA) kit (IBL, Japan), according to the
manufacturer’s protocol.
Statistical analysis
Data are expressed as means ± standard deviations
(SDs). Statistical significance was determined using Stu-
dent’s t-test for comparisons between two means. The
null hypothesis was rejected in cases where p-values
were < 0.05.
Results
Inhibition of ST6Gal I cleavage by knockdown of BACE1
increases sialylation of cell surface protein
In our previous study, we found that IR exposure
induces ST6Gal I cleavage and produces a soluble form
of ST6Gal I in SW480 colon cancer cells [23]. To sup-
port the result of our prior work, we next examined the
expression of soluble ST6 Gal I in SW48 cells (ST6 Gal
I-/-) by transiently transfecting these cells with expres-
sion vectors for Golgi-anchored (N-terminally Flag-
tagged and C-terminally Myc-tagged) of ST6Gal I and
exposing them to IR. As shown in Figure 1A, both the
Golgi-anchored and soluble forms of ST6Gal I were
expressed in SW48 colon cancer cells (Figure 1A).
Because it had previously been demonstrated that sialyl-
transferases are cleaved by cathepsin-like protease or
BACE [3,29,34,37], we sought to identify the target pro-
tease(s) responsible for cleavage of ST6Gal I using var-
ious protease inhibitors in SW480 vector-control and
ST6Gal I-overexpressing cells. Inhibitors of b-secretase
and g-secretase increased the protein levels of the
uncleaved, proform of ST6Gal I, whereas cathepsin B
and L (CTS) inhibitors did not (Figure 1B). In addition,
a2, 6 sialylation level at the cell surface, detected by
FITC-conjugated SNA, was also increased by treatment
with b-secretase or g-secretase, but not CTS, inhibitors.
In contrast, a2, 3 sialylation at the cell surface, detected
by FITC-MAA, was not altered by these inhibitors (Fig-
ure 1C), suggesting that b-secretase or g-secretase might
be responsible for the cleavage of ST6Gal I in SW480
colon cancer cells. Next, because BACE1 is reported to
be the protease responsible for the cleavage of ST6Gal 1
[34,35], we tested the effects of siRNA-mediated BACE1
knockdown. We observed a concomitant increase in the
level of non-cleaved ST6Gal I protein and sialylation of
integrin b1, a substrate of ST6Gal I (Figure 1D). More-
over, knockdown of BACE1 expression augmented the
sialylation on the surface of these cells. Interestingly,
BACE1 overexpression did not specifically inhibit cell
surface sialylation (and may have slightly increased it)
compared with control levels (Figure 1E), suggesting
that BACE1-mediated cleavage of ST6Gal I only slightly
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shows the sialylation potential of ST6Gal I. Taken
together, these results suggest that BACE1 may be
responsible for cleavage of ST6Gal I.
The non-cleavable, double-mutant ST6Gal I (L37A/K40A)
increases a2, 6 sialylation at the cell surface
It was previously demonstrated that replacement of
ST6Gal I residues Leu37 and Lys40 with alanine signifi-
cantly decreases BACE1-mediated cleavage of ST6Gal I
[34]. Therefore, we prepared a N-terminally Flag-tagged
and C-terminally myc-tagged, non-cleavable ST6Gal I
(L37A/K40A) mutant and an HA-tagged, N-terminally
truncated soluble form of ST6Gal I (ΔN, amino acids
43-403) lacking the protease-specific recognition motif
(Figure 2A). We then transiently transfected cells with
ST6Gal I WT, L37A/K40A or ΔN constructs, and exam-
ined ST6Gal I protein expression by immunoblotting
(Figure 2A) and measured ST6Gal I enzymatic activity
and sialylation of cell surface proteins 24 hours later.
We found that the enzymatic activity of both the non-
cleavable L37A/K40A mutant and the ΔN soluble form
was similar to that of WT (Figure 2B). In addition,
L37A/K40A increased cell surface sialylation to a similar
extent as WT. However, in the case of ΔN, which also
had enzymatic catalytic activity, cell surface
glycoproteins were barely sialylated compared to WT or
L37A/K40A (Figure 2C). These results show that the
non-cleavable form of ST6Gal I has enzymatic activity
and increases a2, 6 sialylation at the cell surface to the
same extent as WT. However, it was suggested that the
sialylation targets of the soluble form of ST6Gal I were
not cell surface proteins. This result may be due to the
fact that there isn’t much CMP-sialic acid substrate on
the outside of the cell.
Non-cleaved form ST6Gal I shows integrin b1 dependent
cell migration
Integrin b1, a known substrate of ST6Gal I [4,38],
together with associated adaptor molecules, such as
p130CAS, plays a role in promoting the migration of
cancer cells [39-41]. We previously reported that integ-
rin b1 sialylation and its associated cancer cell migra-
tion-related signaling activity are increased by IR-
induced ST6Gal I [22,23,26]. The phenomena described
above prompted us to compare the action of WT and
non-cleavable L37A/K40A on integrin b1 sialylation,
integrin b1-mediated signaling, and cell migration. As
shown in Figure 3A, transfection with L37A/K40A
increased the Tyr410-phosphorylated (active) form of
p130CAS (p-p130CASY410) and sialylation of integrin b1
Figure 1 Inhibition of BACE1 stabilizes ST6Gal I and increases cell surface sialylation. A. SW48 (ST6Gal I-negative) colon cancer cells were
transiently transfected with an N-terminally Flag-tagged ST6Gal I expression plasmid, and 24 hours later, cells were exposed to IR (10 Gy). Cell
lysates were assessed for expression of ST6Gal I by immunoblotting with an ST6Gal I antibody. B. SW480 vector-control cells and cells stably
expressing ST6Gal I were treated with inhibitors of b-secretase, g-secretase, or cathepsin B&L at a concentration of 20 μM. After incubating for 24
hours, cells were harvested and ST6Gal I levels were analyzed by immunoblotting with an anti-ST6Gal I antibody. C. Cell surface a2, 6 sialylation
(SNA-FITC) and a2, 3 sialylation (MAA-FITC) were analyzed by FACS after 24 hours of treatment with 20 μM b-secretase or g-secretase inhibitors.
D. SW480 cells were transfected with siRNA against BACE1, and the levels of BACE1, ST6Gal I, and integrin b1 protein were assessed by
immunoblotting. Sialylation of integrin b1 was assayed by SNA lectin affinity assay. E. SW480 vector-control cells and cells stably expressing
ST6Gal I were treated with Si-BACE1 or transfected with a BACE1 expression plasmid. Then, a2, 6 sialylation (SNA-FITC) of the cell surface was
analyzed by FACS. Data are presented as means ± SDs of three replicates (*p < 0.05 vs. the corresponding control).
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to a greater degree than did the WT form. Next, we
further examined the effects of BACE1 on ST6Gal I
cleavage by co-transfecting SW480 cells with BACE1
and WT or L37A/K40A forms of ST6Gal I. These
experiments showed that the Golgi-anchored WT pro-
form was decreased to a greater extent by co-transfec-
tion of BACE1 compared with the non-cleavable L37A/
K40A form (Figure 3B). We then extended our investi-
gation of the roles of BACE1 in ST6Gal I-mediated
migration of cancer cells by co-transfecting SW480 and
CT26 cells with BACE1 and WT or L37A/K40A. Cell
migration was increased to a much lesser extent by co-
expression of BACE1 and WT compared with coexpres-
sion of BACE1 and L37A/K40A (Figure 3C). These find-
ings demonstrate that BACE-1 is capable of cleaving the
Golgi-membrane anchored ST6Gal I, and indicate that
BACE-1-induced cleavage of ST6Gal I results in
decreased cell migration.
The soluble form of ST6Gal I is partially involved in the
migration of colon cancer cells
Next, we compared the effects of ST6Gal I WT and ΔN
on integrin b1 sialylation, integrin b1-mediated signal-
ing, and cell migration. Expression of either WT or ΔN
increased the levels of the Tyr410-phosphorylated
(active) form of p130CAS (p-p130CASY410; Figure 4A)
and enhanced cell migration (Figure 4B). Although the
ΔN soluble form had no significant effects on sialylation
of the cell surface glycoprotein integrin b1, it signifi-
cantly induced p130CAS phosphorylation and migration
of SW480 cells (Figure 4A and 4B) and CT26 cells (data
not shown), similar to the results of our previous study
[23,26]. These findings suggest that the soluble form of
ST6Gal I could be involved in p130CAS signaling and
migration of colon cancer cells, which, in turn, may be
independent of integrin b1 sialylation.
BACE-1 mediated cleavage and secretion of ST6Gal I are
increased by IR
Our previous study indicated that IR induces ST6Gal I
cleavage and secretion of a soluble form of ST6Gal I
[23]. Because it has been suggested that BACE1 is a pro-
tease of ST6Gal I, we tested the effect of IR on BACE1
expression. Importantly, IR (10 Gy) increased the
expression of BACE1 at both mRNA and protein levels
in SW480 and CT26 colon cancer cell lines (Figure 5A).
Next, we examined whether IR induced ST6Gal I clea-
vage and produced a soluble form of ST6Gal I. As
shown in Figure 5B, IR increased cleavage of ST6Gal I
and knockdown of BACE1 inhibited this cleavage. In
both SW480 and CT26 cell lines, the enzymatic activity
of ST6Gal I in culture media was increased compared to
that in control cells after exposure of vector control or
ST6Gal I-overexpressing cells to IR (Figure 5C). How-
ever, even though IR alone slightly increased cell surface
protein sialylation which might be induction of ST6Gal
Figure 2 Construction of ST6Gal I expression plasmids and their effect on a2, 6 sialylation at the cell surface. A. Expression plasmids for
full-length WT ST6Gal I (WT), double-mutant ST6Gal I (L37A/K40A) and N-terminal ST6Gal I deletion mutant (ΔN, containing amino acids 43-403)
were constructed. WT and L37A/K40A were N-terminally tagged with Flag; ΔN was tagged with HA. Expression of each construct was confirmed
by immunoblotting. SW480 cells were transfected with WT, L37A/K40A, or ΔN. Then, ST6Gal I enzymatic activity was measured by ELISA (B), and
cell surface sialylation was detected by FACS (C). Data are presented as means ± SDs of three replicates (*p < 0.05 vs. the corresponding
control).
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I by IR [23,24], Golg-anchored ST6Gal I-mediated
increase of cell surface sialylation was not augmented by
IR (Figure 5D). We also checked the effect of IR on
ST6Gal I-induced cell migration. ST6Gal I enhanced
CT26 cell migration, an effect that was partially inhib-
ited by IR. These results indicate that IR acted through
induction of BACE1 expression to induce cleavage of
ST6Gal I protein to a soluble form that retained sialyl-
transferase activity. ST6Gal I-induced cell surface
sialylation and migration were partially inhibited by IR,
an effect that might be due to cleavage of ST6Gal I (Fig-
ure 5E).
Discussion
In the present study, we showed that IR induced clea-
vage and secretion of the soluble form of ST6Gal I by
increasing BACE-1 expression, an effect that may contri-
bute to IR-induced migration of colon cancer cells,
Figure 3 Sialylation and migration effects of non-cleavable ST6Gal I (L37A/K40A). A. SW480 cells were transfected with WT ST6Gal I (WT)
or ST6Gal I (L37A/K40A) and cell lysates were analyzed for the phosphorylated form of p130CAS (p-P130CASY410) and integrin b1 by
immunoblotting. Expression of ST6Gal I was assessed using an anti-Flag antibody. Sialylation of integrin b1 was determined by SNA lectin affinity
assay. B. SW480 cells were co-transfected with BACE1 and the WT or L37A/K40A form of ST6Gal I. Cell lysates were immunoblotted with
antibodies against BACE1 and Flag. C. SW480 cells and CT26 cells were co-transfected with BACE1 and WT or L37A/K40A. Twenty-four hours after
transfection, cell migration was determined using Transwell migration assays. Upper: images of migrated cells captured by phase-contrast
microscopy; lower: migration measured by counting cells. Data are presented as means ± SDs of three replicates (*p < 0.05 vs. the
corresponding control).
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which phenomena is independent of integrin b1 sialyla-
tion that was usually mediated by Golgi-anchored
ST6Gal I.
Our previous study suggested that IR increases the
expression of ST6Gal I, which, in turn, is involved in
radioresistance and radiation-induced migration via sia-
lylation of integrin b1 [22,23,26]. Another interesting
issue raised previously is that IR increases ST6Gal I
cleavage and secretion into culture media [23]. While
the current data indicate that the Golgi is the main site
of sialylation by ST6Gal I in most cells, the fact that
soluble forms of ST6Gal I are detected in body fluids
and media from cultured cells has raised questions con-
cerning the functions of this extracellular ST6Gal I. It is
known that ST6Gal I is not the only transferase that
exists in a soluble form; other glycosyltransferases are
also detected in the systemic circulation of cancer
patients, where they are associated with disease severity
and poor prognosis. It has also been suggested that
soluble ST6Gal I may be a potential biomarker for the
clinical evaluation of colorectal cancer, highlighting the
importance of elucidating the function of soluble
ST6Gal I, particularly in the radiation-induced migration
of cancer cells.
BACE-1, which is a crucial protease in the pathogen-
esis of Alzheimer’s disease, is highly expressed in the
brain, but it is also expressed at low levels in peripheral
tissues. Information regarding BACE-1 expression and
functions outside of the brain is limited. Furthermore,
the physiological importance of BACE-1 in cancer pro-
gression, metastasis, and responsiveness to radiation
remains largely unknown. Evidence that BACE-1 is one
of the proteases responsible for the cleavage of ST6Gal I
was provided by experiments employing a b-secretase
inhibitor or siRNA-mediated knockdown of BACE-1
(Figure 1). The results of these experiments suggest that
BACE1 activity involved in cleavage of ST6Gal I from
the Golgi membrane and inducing secretion.
Interestingly, inhibition of g-secretase also increased
ST6Gal I levels and cell surface sialylation. Although
BACE-1 expression levels could be a major determinant
of ST6Gal I cleavage, other regulatory mechanisms
might also affect cleavage, secretion, or sorting of
ST6Gal I to critical subcellular localizations where
ST6Gal I could encounter proteases. Such BACE-1-
independent mechanisms might also regulate ST6Gal I
function.
In colon cancer cells, IR increased the expression of
BACE1, which is involved in IR-mediated cleavage of
ST6Gal I (Figure 5). To address the detailed mechan-
isms linking ST6Gal I to cancer cell migration, we
established non-cleavable (L37A/K40A) and soluble
(ΔN) variants of ST6Gal I that retained catalytic activity
(Figure 2). Cleaved ST6Gal I was secreted into the
Figure 4 The soluble form of ST6Gal I increases the migration of colon cancer cells. A. SW480 cells were transfected with WT ST6Gal I
(WT) or ST6Gal I-ΔN (ΔN), and cell lysates were analyzed for the phosphorylated form of p130CAS (p-P130CASY410) and integrin b1 by
immunoblotting. Sialylation of integrin b1 was determined by SNA lectin affinity assay. B. After transfection with the WT or ΔN form of ST6Gal I,
cell migration was determined using Transwell migration assays. Upper: images of migrated cells captured by phase-contrast microscopy; lower:
migration measured by counting cells. Data are presented as means ± SDs of three replicates (*p < 0.05 vs. the corresponding control).
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Figure 5 IR-induced BACE-1 mediates cleavage of ST6Gal I, and inhibits sialylation of cell surface molecules and colon cancer cell
migration. A. Following irradiation of SW480 and CT26 cells, BACE1 expression levels were determined by RT-PCR and immunoblotting. CT26
vector control cells and cells stably expressing ST6Gal I were exposed to 10 Gy of IR. B. The soluble form of ST6Gal I was analyzed after co-
transfection with WT ST6Gal I and BACE1, or after exposure of IR (10 Gy, 48 h) to WT ST6Gal I -transfected cells. C. SW480 and CT26 colorectal
carcinoma cell lines were stably transfected with ST6Gal I and exposed to 10 Gy of IR. After 24 hours, culture media were harvested and ST6Gal I
activity was assayed by ELISA. Data are presented as means ± SDs from three replicates. CT26 vector control cells and cells stably expressing
ST6Gal I were exposed to 10 Gy of IR. After 24, a2,6 sialylation of cell surface was analyzed by flow cytometry. Data are presented as means ±
SDs of three replicates. *p < 0.05. n.s., not significant. (D). Cell migration was determined using Transwell migration assays (E). Upper: images of
migrated cells captured by phase-contrast microscopy; lower: migration measured by counting cells. Data are presented as means ± SDs of three
replicates (*p < 0.05 vs. the corresponding control).
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culture media after exposure to radiation (Figure 5), and
the truncated soluble ΔN form retained sialyltransferase
activity (Figure 2). We had predicted that the soluble
form of ST6Gal I was merely a byproduct of the Golgi-
anchored proform of ST6Gal I that was excreted into
the extracellular milieu after exposure of cells to radia-
tion. However, ST6Gal I-ΔN also induced cellular
migration (Figure 4), suggesting that the soluble form of
ST6Gal I could function in tumor cell migration with
unknown mechanism. In addition, it was proposed that
soluble ST6Gal I would catalyze the sialylation of solu-
ble glycoproteins in the trans-Golgi network, or secre-
tory vesicles [35]. These phenomena would be related
with sialylation of unknown glycoproteins in intracellu-
lar region and subsequently have effect on the process
of cell migration. An examination of integrin b1, which
is involved in IR-mediated sialylation and tumor migra-
tion [23,26], showed that the soluble form of ST6Gal I
did not affect the sialylation of integrin b1 (Figure 4).
However, cleavage of ST6Gal I by IR inhibited IR-
induced migration (Figure 5), indicating that increase of
integrin b1-mediated migration by Golgi-anchored
ST6Gal I is more potent phenomena than that of solu-
ble form ST6Gal I.
Therefore, it could be suggested that a transfer of sia-
lic acids that is independent of integrin b1 sialylation
might be involved in soluble ST6Gal I-mediated migra-
tion and activation of p130CAS.
Conclusion
Collectively, our data suggest that glycoconjugation by
the Golgi form of ST6Gal I, possibly in cooperation
with soluble ST6Gal I, may be involved in the process
of cancer metastasis, especially after radiation therapy.
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